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Multivessel Primary PCI
The Debate ContinuesThe CvLPRIT (Complete versus Lesion-only Primary
PCI Trial) (1) investigators welcome the comments of
Dr. Agarwal. CvLPRIT was designed as a pragmatic
trial of treatment strategies in real-world patients:
randomization was carried out therefore on the basis
of angiographic assessment of noninfarct-related ar-
tery (N-IRA) lesion severity as this remains the most
common method for N-IRA lesion assessment during
primary percutaneous coronary intervention (P-PCI).
Pressure-wire assessment is less commonly per-
formed during P-PCI than during catheterization for
stable patients or those presenting with acute coro-
nary syndromes (ACS)/non–ST-segment elevation
myocardial infarction (NSTEMI). We recognize, how-
ever, the growing evidence regarding the limitation
of angiography in deﬁning lesions responsible for
ischemia (2).
Although putative mechanisms of widespread
coronary inﬂammation causing plaque instability
are recognized, potentially predisposing to ischemic
events in N-IRA lesions of even modest severity (for
example, those exhibiting thin-cap ﬁbroatheroma),
this hypothesis remains unproven. No data have yet
emerged suggesting interventionists should make a
paradigm shift from the strategy of ischemia
reduction to that of “plaque stabilization” of non-
ischemic bystander lesions during the post-STEMI
period (3).
Baseline angiographic characteristics of the 2
treatment groups in CvLPRIT were not signiﬁ-
cantly different (1). Despite having three times as
many stents implanted, the complete revasculari-
zation group did not have any increase in stent
thrombosis.
However, CvLPRIT was not designed to answer all
the questions regarding multivessel disease in pa-
tients undergoing P-PCI, only the one that faced us at
the time: “if faced in the catheterization laboratory
with such a patient, should one even consider com-
plete revascularization?” Design of a single deﬁnitivetrial to resolve the unanswered questions surround-
ing STEMI management remains challenging. The
consistency of both CvLPRIT and PRAMI (Preventive
Angioplasty in Myocardial Infarction) in demon-
strating large treatment effects in favor of complete
revascularization undoubtedly inﬂuenced the Amer-
ican College of Cardiology “Choosing Wisely” advice,
which had been against PCI of N-IRA lesions
following STEMI (4).
There remain several unanswered questions. The
need for a single deﬁnitive large study examining
the effect of complete revascularization upon hard
endpoints, comparing complete revascularization
during the index admission with revascularization
at an interval of 6 to 8 weeks and determining the
utility of fractional ﬂow reserve (FFR) guidance, is
urgent.
The CvLPRIT/PRAMI investigators are currently
seeking funding for a large multicenter randomized
study, the PRIMETIME (PRIMary-PCI&N-IRA Evalu-
ation Trial- In-patient v Medical v dEferred str-
ategies) trial. This trial will recruit 2,750 patients
and randomize them to both a treatment strategy
(culprit-only, in-patient complete or staged out-
patient complete at 6 to 8 weeks) and to an
angiographic or FFR-driven N-IRA assessment to
determine outcome in terms of hard clinical end-
points. Expanded mechanistic information will be
available from a large cardiac magnetic resonance
substudy. Other large ongoing trials such as the
COMPLETE trial (Complete vs Culprit-only Revas-
cularization to Treat Multi-vessel Disease After
Primary PCI for STEMI) are also likely to provide
important information in this contentious and un-
resolved area.Damian J. Kelly, MB, ChB, MD
*Anthony H. Gershlick, MB, BS
John P. Greenwood, MB, ChB, PhD, MD
Gerald P. McCann, MB, ChB
*Glenﬁeld Hospital
University Hospitals of Leicester
Glenﬁeld Hospital Groby Road Site
Leicester, Leicestershire LE3 9QP
United Kingdom
E-mail: AGershlick@aol.com
http://dx.doi.org/10.1016/j.jacc.2015.06.1350
Please note: Dr. Gershlick has received lecture fees and advisory board fees from
Abbott Vascular, The Medicines Company, and AstraZeneca. Dr. McCann has
received research grants from Servier, Novartis, and Menarini International. All
other authors have reported that they have no relationships relevant to the
contents of this paper to disclose.
REF ER ENCES
1. Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus
lesion only revascularization in patients undergoing primary percutaneous
Letters J A C C V O L . 6 6 , N O . 1 5 , 2 0 1 5
O C T O B E R 1 3 , 2 0 1 5 : 1 7 3 8 – 4 6
1746coronary intervention for ST elevation myocardial infarction and multi-vessel
disease: The Complete versus Lesion-only Primary PCI Trial (CvLPRIT). J Am
Coll Cardiol 2015;65:963–72.
2. Layland J, Oldroyd KG, Curzen N, et al. Fractional ﬂow reserve vs. angi-
ography in guiding management to optimize outcomes in non-ST-segment
elevation myocardial infarction: the British Heart Foundation FAMOUS-
NSTEMI randomized trial. Eur Heart J 2015;36:100–11.3. Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous
coronary interventions in silent ischemia after myocardial infarction. The
SWISSI II randomized controlled trial. JAMA 2007;297:1985–91.
4. American College of Cardiology. American College of Cardiology updates
heart attack recommendations [press release]. 2014. Available at: http://
www.cardiosource.org/news-media/media-center/news-releases/2014/09/
choosing-wisely-statement.aspx. Accessed September 1, 2014.
